Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo Rep Frowns on Low Manufacturing Cost Disclosure, Says New Rule Might Need Revisiting
May 17, 2018
- Chuikyo Reps Chide Delay in Parmodia Listing
May 17, 2018
- Pricing OK’ed for Hemlibra, Parmodia; Prevymis 1st in 3 Years to Get At-Launch Premium for Innovation
May 17, 2018
- Japan Dodges “Priority Watch List,” but US Global IP Report Still Cites Concerns on Its Drug Pricing
May 16, 2018
- MHLW Approves Once-Daily Form of MSD’s HIV Drug Isentress
May 15, 2018
- Generic Industry to Ponder New Target Indicator for Post-80% Era
May 14, 2018
- Industry Asked for Legislation for Conditional Early Approval and Sakigake Designation Scheme: MHLW Panel
May 11, 2018
- Chugai’s Anticancer Agent Obinutuzumab Up for MHLW Panel Review on May 23
May 11, 2018
- Japanese Regulators Ink Confidential Arrangements with Danish Counterpart
May 8, 2018
- MHLW Panel Backs Xeljanz for Ulcerative Colitis
May 1, 2018
- MHLW Proposes Discussing Proper Use of High-Cost Biologics in Preparation for Revision of RA Measures
April 27, 2018
- Imfinzi Sails through MHLW Panel, Now in Line for Stage III NSCLC Nod
April 26, 2018
- MHLW Starts Discussing Blood Law Amendment Focusing on Use of Blood-Derived iPS Cells, New Entrants into Blood Collection
April 26, 2018
- Patients Won’t Benefit without Change in Mindset among Researchers: AMED President
April 25, 2018
- ICER-Based Price Tweaks “Scientifically Difficult,” Impact on Cost Cuts Limited: Prof.
April 25, 2018
- Tap Data from “Specified Clinical Research” for Early Trial, Conditional Approval: JPMA Official
April 24, 2018
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR
April 20, 2018
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official
April 19, 2018
- Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab
April 17, 2018
- No Company Supports New Price Maintenance Premium Scheme: FPMAJ Survey
April 17, 2018
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…